The World Health Organization has declared mpox an international emergency. Shares of Siga Technologies (SIGA), whose lead product is an antiviral drug for the treatment of human smallpox disease, are up 20% to $10.98 following the news. In December 2023, GeoVax Labs (GOVX) announced that it had amended a previously executed Patent and Biological Materials License Agreement with the National Institute of Allergy and Infectious Diseases to expand GeoVax’s commercial license to include mpox and smallpox as additional indications. The company’s shares are up 20% to $3.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SIGA:
- WHO to consider emergency as Mpox resurfaces in Africa, News Central reports
- Siga Technologies reports Q2 EPS 3c VS. (4c) last year
- SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results
- SIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX®
- Siga Technologies announces U.S. government procurement order of $113M